Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Effectiveness of Montelukast in Reducing the Risk of Severe Dengue in Dengue Fever Patients: An Evidence-Based Case Report

ACTA MEDICA INDONESIANA · Vol. 58 No. 1 (2026)

ISSN
2338-2732, 0125-9326
Terbit
2026-04-09
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng
Lisensi
creativecommons.org/licenses/by/4.0

Abstrak

Background: Dengue fever continues to spread worldwide, particularly in tropical regions. Some patients with dengue fever may progress to severe dengue, which is associated with significantly higher morbidity and mortality. Despite this, no definitive treatment has been found to prevent its progression. Montelukast, a leukotriene receptor antagonist, has shown potential in reducing plasma leakage, a key factor in the pathophysiology of severe dengue. Therefore, this study aimed to evaluate the effectiveness of montelukast in reducing the risk of severe dengue. Methods: A systematic literature search was conducted on April 16, 2025, using keywords related to montelukast and dengue across four databases, which included PubMed, Taylor and Francis, Cochrane Library, and ScienceDirect. A critical appraisal was performed using the Oxford Centre for Evidence-Based Medicine framework, evaluating the validity, importance, and applicability of each study. The primary outcomes were the incidence of dengue shock syndrome and dengue with warning signs. The secondary outcomes included mortality rate and hospitalization duration. Results: This study included three studies involving a total of 1057 patients. Montelukast is associated with a reduced incidence of dengue shock syndrome and shorter duration of hospitalization. However, the effect of montelukast on dengue with warning signs and mortality rate was inconclusive. Conclusion: Montelukast shows potential as an adjuvant therapy in preventing the progression of dengue fever to severe dengue. However, further research is required before montelukast can be widely recommended for dengue fever patients in daily clinical practice and possibly integrated into dengue fever clinical guidelines.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 167 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Khie Chen LieAfiliasi tidak diketahui19
Robert SintoAfiliasi tidak diketahui18
Adeline PasaribuAfiliasi tidak diketahui11
Cleopas Martin RumendeAfiliasi tidak diketahui5
Rahajeng N TunjungputriAfiliasi tidak diketahui3
Hamzah ShatriAfiliasi tidak diketahui3
Randy AdiwinataAfiliasi tidak diketahui3
Ikhwan RinaldiAfiliasi tidak diketahui3
Mulya Rahma KaryantiAfiliasi tidak diketahui2
Adeline Intan PasaribuAfiliasi tidak diketahui2
Irsan HasanAfiliasi tidak diketahui2
Djoko WidodoAfiliasi tidak diketahui2
Erni J NelwanAfiliasi tidak diketahui2
Adityo SusiloAfiliasi tidak diketahui2
Murdani AbdullahAfiliasi tidak diketahui2
Suhendro SuhendroAfiliasi tidak diketahui1
Cleopas M RumendeAfiliasi tidak diketahui1
Eppy EppyAfiliasi tidak diketahui1
Esthika DewiastyAfiliasi tidak diketahui1
Candra WigunaAfiliasi tidak diketahui1
Iqbal Zein AssyidiqieAfiliasi tidak diketahui1
Hindra Irawan SatariAfiliasi tidak diketahui1
Sri Rezeki HadinegoroAfiliasi tidak diketahui1
Narottama TunjungAfiliasi tidak diketahui1
Helio GuterresAfiliasi tidak diketahui1
Ralalicia LimatoAfiliasi tidak diketahui1
Muhadi MuhadiAfiliasi tidak diketahui1
Pringgodigdo NugrohoAfiliasi tidak diketahui1
Kresna Dharma SuryanaAfiliasi tidak diketahui1
Beryl AlodiaAfiliasi tidak diketahui1
Erpryta N TetrasiwiAfiliasi tidak diketahui1
Richella K LaudittaAfiliasi tidak diketahui1
Samuel Theodorus SutantoAfiliasi tidak diketahui1
Aulia RizkaAfiliasi tidak diketahui1
Soekamto KoesnoeAfiliasi tidak diketahui1
Rohayat Bilmahdi SimanjuntakAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Effectiveness of Montelukast in Reducing the Risk of Severe Dengue in Dengue Fever Patients: An Evidence-Based Case Report</dc:title>
	<dc:creator>Wijaya, Nicholas Jason </dc:creator>
	<dc:creator>Shakinah, Sharifah</dc:creator>
	<dc:creator>Nainggolan, Leonard </dc:creator>
	<dc:creator>Nelwan, Erni Juwita</dc:creator>
	<dc:subject xml:lang="en-US">evidence-based case report</dc:subject>
	<dc:subject xml:lang="en-US">severe dengue</dc:subject>
	<dc:subject xml:lang="en-US">dengue fever</dc:subject>
	<dc:subject xml:lang="en-US">leukotriene receptor antagonist</dc:subject>
	<dc:subject xml:lang="en-US">montelukast</dc:subject>
	<dc:description xml:lang="en-US">Background: Dengue fever continues to spread worldwide, particularly in tropical regions. Some patients with dengue fever may progress to severe dengue, which is associated with significantly higher morbidity and mortality. Despite this, no definitive treatment has been found to prevent its progression. Montelukast, a leukotriene receptor antagonist, has shown potential in reducing plasma leakage, a key factor in the pathophysiology of severe dengue. Therefore, this study aimed to evaluate the effectiveness of montelukast in reducing the risk of severe dengue. Methods: A systematic literature search was conducted on April 16, 2025, using keywords related to montelukast and dengue across four databases, which included PubMed, Taylor and Francis, Cochrane Library, and ScienceDirect. A critical appraisal was performed using the Oxford Centre for Evidence-Based Medicine framework, evaluating the validity, importance, and applicability of each study. The primary outcomes were the incidence of dengue shock syndrome and dengue with warning signs. The secondary outcomes included mortality rate and hospitalization duration. Results: This study included three studies involving a total of 1057 patients. Montelukast is associated with a reduced incidence of dengue shock syndrome and shorter duration of hospitalization. However, the effect of montelukast on dengue with warning signs and mortality rate was inconclusive. Conclusion: Montelukast shows potential as an adjuvant therapy in preventing the progression of dengue fever to severe dengue. However, further research is required before montelukast can be widely recommended for dengue fever patients in daily clinical practice and possibly integrated into dengue fever clinical guidelines. </dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2026-04-09</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/3306</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 58 No. 1 (2026): Acta Medica Indonesiana; 115</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/3306/857</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2026 Nicholas Jason  Wijaya, Sharifah Shakinah, Leonard  Nainggolan, Erni Juwita Nelwan</dc:rights>
	<dc:rights xml:lang="en-US">https://creativecommons.org/licenses/by/4.0</dc:rights>
</oai_dc:dc>